Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 149Breast Neoplasms 87Colorectal Neoplasms 64Neoplasms 53Pancreatic Neoplasms 52Lung Neoplasms 49Neoplasm Metastasis 45Stomach Neoplasms 43Ovarian Neoplasms 42Rectal Neoplasms 41Esophageal Squamous Cell Carcinoma 34Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 30Head and Neck Neoplasms 30Leukemia, Myeloid, Acute 28Recurrence 23Triple Negative Breast Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Small Cell Lung Carcinoma 20Nasopharyngeal Carcinoma 20Glioblastoma 20Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Lymphoma, Non-Hodgkin 18Lymphoma 18Colonic Neoplasms 17Prostatic Neoplasms 16Leukemia 15Carcinoma, Ovarian Epithelial 15Melanoma 14

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1atezolizumab 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Select Advanced Solid Tumors × Drug Therapy × Clear all
NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡